A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia

In this study, we show that combined use of Imatinib (IM) and arsenic sulfide [As4S4 (AS)] exerts more profound therapeutic effects in a BCR/ABL-positive mouse model of chronic myeloid leukemia (CML) than either drug as a single agent. A systematic analysis of dynamic changes of the proteome, phosphoproteome, and transcriptome in K562 cells after AS and/or IM treatment was performed to address the mechanisms underlying this synergy. Our data indicate that AS promotes the activities of the unfolded protein reaction (UPR) and ubiquitination pathway, which could form the biochemical basis for the pharmacological effects of this compound. In this CML model, AS targets BCR/ABL through the ubiquitination of key lysine residues, leading to its proteasomal degradation, whereas IM inhibits the PI3K/AKT/mTOR pathway. Combination of the 2 agents synergistically arrests the cell cycle, decreases activity of BCR/ABL, and leads to activation of intrinsic and extrinsic apoptosis pathways through complex modifications to both transcription and protein levels. Thus, these results suggest potential clinical benefits of IM/AS combination therapy for human CML.

[1]  D. Kirkpatrick,et al.  Low-level arsenite causes accumulation of ubiquitinated proteins in rabbit renal cortical slices and HEK293 cells. , 2003, Toxicology and applied pharmacology.

[2]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[3]  C. Dang,et al.  Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Andreas Hochhaus,et al.  Chronic myeloid leukaemia , 2007, The Lancet.

[5]  E. T. Snow,et al.  In vitro effect of arsenical compounds on glutathione-related enzymes. , 2001, Chemical research in toxicology.

[6]  R. Arceci.  PML targeting eradicates quiescent leukaemia-initiating cells , 2009 .

[7]  P. Hogg,et al.  Presence of closely spaced protein thiols on the surface of mammalian cells , 2000, Protein science : a publication of the Protein Society.

[8]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[9]  Kui Wang,et al.  Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by arsenic sulphide: involvement of serine/threonine protein phosphatases. , 2006, Leukemia research.

[10]  Charles Auffray,et al.  Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Wallace,et al.  Arsenic Trioxide Affects Signal Transducer and Activator of Transcription Proteins through Alteration of Protein Tyrosine Kinase Phosphorylation , 2006, Clinical Cancer Research.

[12]  K. Bhalla,et al.  Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). , 2000, Blood.

[13]  C. Kenific,et al.  Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. , 2006, Cancer research.

[14]  X Zhang,et al.  Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. , 1998, Blood.

[15]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.

[16]  Wilfred W. Li,et al.  The tumor promoter arsenite stimulates AP‐1 activity by inhibiting a JNK phosphatase. , 1996, The EMBO journal.

[17]  B. Druker,et al.  In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. , 2002, Experimental hematology.

[18]  Kalle Gehring,et al.  Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b. , 2007, Molecular cell.

[19]  Jie Wu,et al.  Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells. , 2003, Cancer research.

[20]  T. Rossman,et al.  Expression cloning for arsenite-resistance resulted in isolation of tumor-suppressor fau cDNA: possible involvement of the ubiquitin system in arsenic carcinogenesis. , 1999, Carcinogenesis.

[21]  Michael Sattler,et al.  Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl. , 2005, Molecular cell.

[22]  P. S. Kim,et al.  Structure of the Bcr-Abl oncoprotein oligomerization domain , 2002, Nature Structural Biology.

[23]  Saijuan Chen,et al.  Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia , 2008, Proceedings of the National Academy of Sciences.

[24]  Michael G. Kharas,et al.  ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. , 2005, Cancer research.

[25]  Guoqiang Chen,et al.  Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. , 2004, Blood.

[26]  C. Schiffer,et al.  BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. , 2007, The New England journal of medicine.

[27]  Charles Auffray,et al.  Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. , 2005, Blood.

[28]  T. Hall,et al.  Combination therapy of adult acute myelogenous leukemia: experience with the simultaneous use of vincristine, amethopterin, 6-mercaptopurine and prednisone. , 1965, The New England journal of medicine.

[29]  L. Neckers,et al.  The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[30]  Zhi-xiang Shen,et al.  Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia , 2008, Proceedings of the National Academy of Sciences.

[31]  Xianglin Shi,et al.  Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin–proteasome pathway , 2002, Proceedings of the National Academy of Sciences of the United States of America.